ACC Current Clinical Trials - Consult Coordinator at 970.297.4195  
     
 
  Radiation Oncology Trials:
    Feline Pituitary Tumor & Stereotactic RT Study: To determine the best protocol to eliminate the pituitary tumor, to document the effects of stereotactic radiation therapy on pituitary function, and to monitor the resolution of endocrine disease after stereotactic radiation therapy. (Internal study)
         
    Acute Effects RT Study: This project will evaluate the impact of small and large doses on both the tumor and surrounding normal tissues. (Externally funded)
         
    Late Effects RT Study: This project will identify patients who would be at risk for re-irradiation. This study will determine blood and oxygen perfusion to tumor and normal tissue beds as well as any changes in bone density in treated and untreated regions. (Externally funded)
         
  Complementary and Alternative Medicine (CAM) Trials:
    Acupuncture Study: Electro-acupuncture and the effects of acupuncture on blood flow in tumors. (Internal study)
         
  Chemotherapy Trials:
    Feline VAS CCNU Study: Designed to evaluate the response rate of cats with measurable VAS treated with lomustine chemotherapy as the sole treatment. In addition, treatment side effects will be assessed. The long-term goal of this clinical trial is to identify a new treatment to prolong the survival and improve quality of life for cats with VAS.
         
    Canine LSA Doxorubicin/Cyclophosphamide Study: The purpose of this study is to evaluate the effectiveness of this protocol.
         
    PEG-TNF/Doxorubicin Study: The goal of this study is to determine how much DOX can be safely given when preceded by PEG-TNF, and whether there is evidence of better anti-tumor activity when the combination is used.
         
  Novel Therapy/Treatment Trials:
    LSA GS-9219 Study: The purpose of this study is to further evaluate the efficacy of GS-9219 and its delivery to tumor cells.
         
    Splenic HSA PEG-TNF Study: The goal of this study is to determine whether administration of PEG-TNF can improve the outcome in dogs with hemangiosarcoma of the spleen.
         
    MM GS-9219 Study: The purpose of this study is to determine whether GS-9219 has anti-tumor activity in dogs with multiple myeloma.
         
    OSA FasL Study: In this clinical study, we plan to establish the safety of this gene therapy in the canine patient as well as demonstrate its effectiveness in the treatment of osteosarcoma.
         
    PEG-TNF/Doxorubicin Study: The goal of this study is to determine how much DOX can be safely given when preceded by PEG-TNF, and whether there is evidence of better anti-tumor activity when the combination is used.
         
    VPA/Doxorubicin Study: The goal of this study is to determine the maximum tolerated dose of VPA that can be administered for 72 hours to tumor-bearing dogs, when followed by a standard dose of DOX.
         
  Imaging
    LSA NMR Study: We are studying the metabolism of lymphoma before and after chemotherapy to better understand this disease. We are looking for specific tumor markers or molecules to tell us how malignant the cancer is, and to better predict how treatable the cancer will be.
         
    LSA Spectroscopy Study: We are studying the metabolism of lymphoma before and after chemotherapy to better understand this disease. We are looking for specific tumor markers or molecules to tell us how malignant the cancer is, and to better predict how treatable the cancer will be.
         
         
Other Trials
         
  Cancer Immunology:
    OSA Regulatory T-Cell Study: Designed to measure the number of regulatory T cells to help better predict the prognosis or response to treatment.
         
  Cancer Diagnostics and Staging:
    Sentinel LN Study: The purpose of this study is to evaluate the accuracy of this technique in locating and then in evaluating the sentinel lymph node for metastasis.
         
  Cancer Biology:
    Zubrin Study: The goal of this study is to determine whether ZubrinÒ is capable of changing the production of one particular growth factor in blood and tumor tissue.
 
     
  Consult Coordinator at 970.297.4195  
     
 
 
Copyright © 2007 NeoTREX. All rights reserved.
 
NeoTREX Colorado State University